ArriVent BioPharma (AVBP) Net Cash Flow (2023 - 2026)
ArriVent BioPharma (AVBP) reported Net Cash Flow of $16.6 million for Q1 2026, up 167.8% on a YoY basis from $6.2 million in Q1 2025, and up 124.67% sequentially from -$67.1 million in Q4 2025.
ArriVent BioPharma (AVBP) Net Cash Flow (2023 - 2026) Analysis & Trends
ArriVent BioPharma (AVBP) has 4 years of Net Cash Flow data on file, last reported at $16.6 million in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow rose 167.8% year-over-year to $16.6 million; the trailing twelve-month figure through Mar 2026 stood at $12.2 million (up 116.3% YoY), and the FY2025 full-year result was -$28.8 million, up 62.21% from the prior year.
- Net Cash Flow climbed to $16.6 million in Q1 2026, from -$67.1 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $167.0 million in Q1 2024 to a low of -$67.1 million in Q4 2025.
- A 4-year average of $7.0 million and a median of -$15.8 million in 2024 frame the typical range for Net Cash Flow.
- Across the five-year window, Net Cash Flow soared 494.57% in 2024 and sank 317.05% in 2025, its largest moves.
- Tracing AVBP's Net Cash Flow over 4 years: stood at -$16.0 million in 2023, then slipped by 0.8% to -$16.1 million in 2024, then slumped by 317.05% to -$67.1 million in 2025, then soared by 124.67% to $16.6 million in 2026.
- Business Quant data shows AVBP's Net Cash Flow at $16.6 million in Q1 2026, -$67.1 million in Q4 2025, and -$93000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | ArriVent BioPharma | 1.42 Bn | 1.42 Bn | - | 16.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.56 Mn |
| Mar 31, 2026 | 16.56 Mn |
| Dec 31, 2025 | -67.13 Mn |
| Dec 31, 2025 | -67.13 Mn |
| Sep 30, 2025 | -93,000.00 |
| Sep 30, 2025 | -93,000.00 |
| Jun 30, 2025 | 62.90 Mn |
| Jun 30, 2025 | 62.90 Mn |
| Mar 31, 2025 | -24.43 Mn |
| Mar 31, 2025 | -24.43 Mn |
| Dec 31, 2024 | -16.10 Mn |
| Dec 31, 2024 | -16.10 Mn |
| Sep 30, 2024 | -15.81 Mn |
| Sep 30, 2024 | -15.81 Mn |
| Jun 30, 2024 | -18.72 Mn |
| Jun 30, 2024 | -18.72 Mn |
| Mar 31, 2024 | 167.00 Mn |
| Mar 31, 2024 | 167.00 Mn |
| Dec 31, 2023 | -15.97 Mn |
| Dec 31, 2023 | -15.97 Mn |